Nikolaus McFarland, MD
Neurology · Gainesville, FLNPI 1962460915
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Roche Products Limited at 57.4% of the total. 2023 is the largest year on record at $185, 2.0 times the $91 reported in 2019. That places this record below the midpoint for neurology clinicians in FL, where the typical reported total is $1,698.
Across 4 payments — averaging $80.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$185
- Genentech USA, Inc.$91
- Carestream Dental, LLC$47
Across 192 payments — averaging $5409.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$254K
- AbbVie$229K
- H. Lundbeck A S$207K
- Genentech, Inc.$125K
- Biogen$109K
- Biohaven Pharmaceuticals, Inc.$51K
- plus $63K from 2 others
What the payments were for
- Food & beverage$323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 1 | $185 |
| Genentech USA, Inc. | 1 | $91 |
| Carestream Dental, LLC | 2 | $47 |
How this compares
$323 in reported general payments places this provider in the 25th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 21 | $192,449 |
| AustedoDeutetrabenazine | 11 | $99,752 |
| NuplazidPimavanserin Tartrate | 20 | $92,867 |
| RytaryCarbidopa/Levodopa | 48 | $63,335 |
| InbrijaLevodopa | 11 | $20,723 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 464 | $19,776 |
| Droxidopa | 12 | $7,133 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 173 | $6,182 |
| Tetrabenazine | 22 | $5,625 |
| Midodrine Hcl | 29 | $3,352 |
| AmantadineAmantadine Hcl | 45 | $2,733 |
| Selegiline Hcl | 14 | $1,931 |
| Primidone | 49 | $1,727 |
| Memantine Hcl | 40 | $1,591 |
| Donepezil Hcl | 124 | $1,411 |
Paid to pharmacies, not to this prescriber.
Other neurology in Gainesville
- Adolfo Ramirez ZamoraGainesville$363K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.